Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf080 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2025. Verfasst von Jean-Frédéric Blanc und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Gastroenterology and Medical Oncology, University of Bordeaux Hospital, Haut Leveque Hospital, 33600 Pessac, France. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Pyridines, Deoxycytidine, Phenylurea Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer Healthcare SAS.
Abstract (Originalsprache)
Background
New therapeutic options are needed for biliary tract cancer (BTC). Regorafenib, a multikinase inhibitor, shows promise in refractory digestive cancers and may be beneficial with conventional chemotherapy for BTC. Patients and Methods The BREGO study evaluated regorafenib with modified gemcitabine-oxaliplatin (mGEMOX) in advanced or metastatic BTC. Phase I determined the recommended dose (RP2D) of regorafenib (80, 120 or 160 mg, days 1-14) combined with mGEMOX (gemcitabine 900 mg.m−2 IV, 30 min, followed by oxaliplatin 80mg.m−2 IV, 120 min, days 1 and 8). Phase II randomized (1:2) patients to mGEMOX alone (arm A) or mGEMOX + regorafenib (arm B, RP2D, days 1-14), assessing efficacy and safety, with the primary outcome being progression-free survival (PFS). Metabolic tumor features and response were also assessed.
Results
In phase Ib, 22 patients were enrolled; in phase II, 66 patients (arm A, n = 24; arm B, n = 42). Four dose-limiting toxicities were observed, but no maximum tolerated dose was reached. The RP2D was 160 mg.d−1. Median PFS (7.2 vs7.8 months; P = .825) and overall survival (15.1 vs 13.5 months; P = .356) were similar between arms. However, posttreatment 18F-FDG tumor uptake (SULpeak) significantly correlated with PFS (P = .001) and OS (P = .016). Baseline plasma stanniocalcin 1 levels < 265 pg.mL−1 were associated with longer PFS (P = .030) and OS (P = .060) in both arms.
Conclusions
Combining regorafenib and mGEMOX is feasible as first-line treatment for BTC but did not increase PFS as expected in the phase II cohort. Identifying new biomarkers can help target patients with advanced BTCs who may benefit from regorafenib-associated therapy. Trial registration number ClinicalTrials.gov, NCT02386397.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Gastroenterology and Medical Oncology, University of Bordeaux Hospital, Haut Leveque Hospital, 33600 Pessac, France.
- AP-HP, Liver Cancer and Innovative Therapy, Beaujon Hospital, 92110 Clichy, France.
- Inserm U1149, Inflammation Research Center (CRI), Paris Cité University, 75018 Paris, France.
- Biometrics Unit, Montpellier Cancer Institute (ICM), Montpellier University, 34298 Montpellier Cedex 5, France.
- Department of Nuclear Medicine, Montpellier Cancer Institute (ICM), Montpellier University, 34298 Montpellier Cedex 5, France.
- Inserm U1194, Montpellier Cancer Research Institute (IRCM), Montpellier University, 34298 Montpellier Cedex 5, France.
ORCID-Profile: Jean-Frédéric Blanc, Mohamed Bouattour, Emmanuel Deshayes, Sophie Guillemard, Yann Touchefeu, Fabienne Portales, Lobna Harguem, Rosine Guimbaud, Marc Ychou, Thibault Mazard, Eric Assenat
Förderung
- Bayer Healthcare SAS
Zitieren
APA
Blanc, J. F., Bouattour, M., Gauthier, L., Deshayes, E., Guillemard, S., Touchefeu, Y., Portales, F., Borg, C., Harguem, L., Guimbaud, R., Mineur, L., Ychou, M., Mazard, T., & Assenat, E. (2025). Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf080
Vancouver
Blanc JF, Bouattour M, Gauthier L, Deshayes E, Guillemard S, Touchefeu Y, et al. Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf080
BibTeX
@article{Blanc2025,
author = {Blanc, Jean-Frédéric and Bouattour, Mohamed and Gauthier, Ludovic and Deshayes, Emmanuel and Guillemard, Sophie and Touchefeu, Yann and Portales, Fabienne and Borg, Christophe and Harguem, Lobna and Guimbaud, Rosine and Mineur, Laurent and Ychou, Marc and Mazard, Thibault and Assenat, Eric},
title = {Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf080}
}
EUVIMED